- Home
- / SkinBioTherapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
SkinBioTherapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
£0.2
2024-10-29
Market Capitalization
£40.5 M
2024-10-29
Revenue
£4.6 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| GBP | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 75.0K | 132.0K | 1.2M | 4.6M | ||||
| Cost of goods sold | 30.0K | 47.0K | 526.0K | 1.8M | ||||
| Gross profit | 1.0K | 46.0K | 88.0K | 699.0K | 2.9M | |||
| Gross profit margin, % | 61.3% | 66.7% | 57.8% | 61.8% | ||||
| Operating expense total | 941.0K | 1.4M | 1.6M | 1.5M | 3.0M | 3.0M | 3.4M | 3.8M |
| Depreciation and amortization | 5.0K | 29.0K | 43.0K | 85.0K | 153.0K | |||
| EBITDA | (941.0K) | (1.4M) | (1.6M) | (1.5M) | (3.0M) | (2.9M) | (2.7M) | (886.0K) |
| EBITDA margin, % | -3936.0% | -2213.6% | -227.0% | -19.1% | ||||
| EBIT | (941.0K) | (1.4M) | (1.6M) | (1.5M) | (3.0M) | (3.0M) | (2.8M) | (539.0K) |
| EBIT margin, % | -3974.7% | -2246.2% | -234.1% | -11.6% | ||||
| Interest expense | 1.0K | 10.0K | 9.0K | 52.0K | 92.0K | |||
| Pre tax profit | (941.0K) | (1.4M) | (1.6M) | (1.5M) | (3.0M) | (3.0M) | (2.9M) | (715.0K) |
| Income tax expense | (97.0K) | (213.0K) | (120.0K) | (65.0K) | (199.0K) | (173.0K) | (73.0K) | (19.0K) |
| Net Income | (844.0K) | (1.1M) | (1.5M) | (1.4M) | (2.8M) | (2.8M) | (2.9M) | (696.0K) |